US3885046A
(en)
|
1969-12-04 |
1975-05-20 |
Burroughs Wellcome Co |
Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
|
BE759838A
(fr)
|
1969-12-04 |
1971-06-03 |
Wellcome Found |
Cetones a activite biologique
|
US3942641A
(en)
|
1972-05-05 |
1976-03-09 |
Syntex Corporation |
Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
|
US4089855A
(en)
|
1976-04-23 |
1978-05-16 |
Cornell Research Foundation, Inc. |
Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
|
US4218433A
(en)
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
US4217353A
(en)
|
1978-05-19 |
1980-08-12 |
E. I. Du Pont De Nemours And Company |
Method for inducing anorexia
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
IL58649A
(en)
|
1978-11-10 |
1982-04-30 |
Beecham Group Ltd |
Pharmaceutical dispensing container
|
ZA824382B
(en)
|
1981-07-07 |
1984-02-29 |
Wyeth John & Brother Ltd |
Anti-obesity agents
|
JPS58134019A
(ja)
|
1982-02-05 |
1983-08-10 |
Ono Pharmaceut Co Ltd |
プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
|
EP0103636B1
(en)
|
1982-03-16 |
1990-09-12 |
Rockefeller University |
Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
|
US4513006A
(en)
|
1983-09-26 |
1985-04-23 |
Mcneil Lab., Inc. |
Anticonvulsant sulfamate derivatives
|
US4689332A
(en)
|
1984-04-09 |
1987-08-25 |
Research Corporation |
Growth regulation and related applications of opioid antagonists
|
US5266574A
(en)
|
1984-04-09 |
1993-11-30 |
Ian S. Zagon |
Growth regulation and related applications of opioid antagonists
|
US4673679A
(en)
|
1986-05-14 |
1987-06-16 |
E. I. Du Pont De Nemours And Company |
Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
|
GB8613689D0
(en)
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
US4895845A
(en)
|
1986-09-15 |
1990-01-23 |
Seed John C |
Method of assisting weight loss
|
NL8800823A
(nl)
|
1987-04-10 |
1988-11-01 |
Sandoz Ag |
Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
|
DE3883606T2
(de)
|
1987-05-04 |
1994-01-20 |
Lilly Co Eli |
Verwendung von Fluoxetin zur Behandlung des Diabetes.
|
US5000886A
(en)
|
1987-05-26 |
1991-03-19 |
American Cyanamid Company |
Silicone-hardened pharmaceutical microcapsules and process of making the same
|
US5364841A
(en)
|
1988-01-11 |
1994-11-15 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and essential hypertension and related disorders
|
US4831031A
(en)
|
1988-01-22 |
1989-05-16 |
Pfizer Inc. |
Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US5114976A
(en)
|
1989-01-06 |
1992-05-19 |
Norden Michael J |
Method for treating certain psychiatric disorders and certain psychiatric symptoms
|
US5202128A
(en)
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
AU5439890A
(en)
|
1989-05-09 |
1990-11-29 |
Whitby Research, Inc. |
A method of reducing body weight and food intake using a dopamine d2 receptor agonist
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
ES2062310T3
(es)
|
1989-12-06 |
1994-12-16 |
Akzo Nv |
Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
|
FR2657350B1
(fr)
|
1990-01-19 |
1992-05-15 |
Centre Nat Rech Scient |
Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
|
US5028612A
(en)
|
1990-03-22 |
1991-07-02 |
Hillel Glover |
Method for treating emotional numbness
|
US5213807A
(en)
|
1990-05-03 |
1993-05-25 |
Chemburkar Pramod B |
Pharmaceutical composition containing ibuprofen and a prostaglandin
|
US5403595A
(en)
|
1991-05-07 |
1995-04-04 |
Dynagen, Inc. |
Controlled, sustained release delivery system for smoking cessation
|
US5486362A
(en)
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
DE4136215A1
(de)
|
1991-11-02 |
1993-05-06 |
Ferring Arzneimittel Gmbh, 2300 Kiel, De |
Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
US5312925A
(en)
|
1992-09-01 |
1994-05-17 |
Pfizer Inc. |
Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
|
IT1255522B
(it)
|
1992-09-24 |
1995-11-09 |
Ubaldo Conte |
Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
|
IT1256393B
(it)
|
1992-11-17 |
1995-12-04 |
Inverni Della Beffa Spa |
Forme matriciali multistrato per il rilascio controllato di principi attivi
|
US5512593A
(en)
|
1993-03-02 |
1996-04-30 |
John S. Nagle |
Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US6183778B1
(en)
|
1993-09-21 |
2001-02-06 |
Jagotec Ag |
Pharmaceutical tablet capable of liberating one or more drugs at different release rates
|
IT1265240B1
(it)
|
1993-11-30 |
1996-10-31 |
Ekita Investments Nv |
Compressa farmaceutica a rilascio controllato, di forma lenticolare
|
EP0782445B1
(en)
|
1994-09-19 |
2002-03-13 |
Dupont Pharmaceuticals Company |
Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
|
US5627187A
(en)
|
1995-04-12 |
1997-05-06 |
Katz; Bruce E. |
5-FU for treating actinic kerotoses
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
WO1997006787A2
(en)
|
1995-08-17 |
1997-02-27 |
Dyer, Alison, Margaret |
Controlled release products
|
GB9517062D0
(en)
|
1995-08-18 |
1995-10-25 |
Scherer Ltd R P |
Pharmaceutical compositions
|
ATE211906T1
(de)
|
1996-03-12 |
2002-02-15 |
Alza Corp |
Zusammensetzung und dosisform mit einem opioid- antagonisten
|
US5716976A
(en)
|
1996-03-13 |
1998-02-10 |
Bernstein; Richard K. |
Method of treatment for carbohydrate addiction
|
EP0795327A1
(en)
|
1996-03-13 |
1997-09-17 |
Pfizer Inc. |
Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
|
EP0828489A4
(en)
|
1996-03-13 |
2001-04-04 |
Univ Yale |
Smoking cessation treatment using naltrexone and related compounds
|
DE69736928T2
(de)
|
1996-05-07 |
2007-06-28 |
Pliva Istrazivanje I Razvoj D.O.O. |
Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
|
IL121076A
(en)
|
1996-06-19 |
2000-10-31 |
Akzo Nobel Nv |
Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
|
US6087386A
(en)
|
1996-06-24 |
2000-07-11 |
Merck & Co., Inc. |
Composition of enalapril and losartan
|
RU2214241C2
(ru)
|
1996-06-28 |
2003-10-20 |
Орто-Макнейл Фармасьютикал, Инк. |
Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
|
US5878750A
(en)
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
FR2758723B1
(fr)
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
CA2216215A1
(en)
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
US6120803A
(en)
|
1997-08-11 |
2000-09-19 |
Alza Corporation |
Prolonged release active agent dosage form adapted for gastric retention
|
US6622036B1
(en)
|
2000-02-09 |
2003-09-16 |
Cns Response |
Method for classifying and treating physiologic brain imbalances using quantitative EEG
|
ATE232384T1
(de)
|
1997-10-03 |
2003-02-15 |
Cary Medical Corp |
Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
|
US6652882B1
(en)
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6262049B1
(en)
|
1997-10-28 |
2001-07-17 |
Schering Corporation |
Method of reducing nicotine and tobacco craving in mammals
|
IL127497A
(en)
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
DE69830512T2
(de)
|
1997-12-26 |
2006-03-23 |
Dainippon Pharmaceutical Co., Ltd. |
Medikament für neurodegenerative Erkrankungen
|
EA002410B1
(ru)
|
1998-01-21 |
2002-04-25 |
Глаксо Груп Лимитед |
Фармацевтически активный морфолинол
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
US6048322A
(en)
|
1998-04-15 |
2000-04-11 |
Kushida; Clete |
Morphometric measurement tool
|
US6153223A
(en)
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6150366A
(en)
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US6096341A
(en)
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6033686A
(en)
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
EP1005863A1
(en)
|
1998-12-04 |
2000-06-07 |
Synthelabo |
Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
|
US20030144174A1
(en)
|
1998-12-09 |
2003-07-31 |
Miles B. Brennan |
Methods for identifying compounds useful for the regulation of body weight and associated conditions
|
US6238697B1
(en)
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
HUP0200469A3
(en)
|
1999-02-24 |
2003-03-28 |
Univ Cincinnati Cincinnati |
Use of sulfamate derivatives for treating impulse control disorders
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6589553B2
(en)
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US20030035840A1
(en)
|
2001-02-08 |
2003-02-20 |
Boyong Li |
Controlled release oral dosage form
|
US8545880B2
(en)
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6387956B1
(en)
|
1999-03-24 |
2002-05-14 |
University Of Cincinnati |
Methods of treating obsessive-compulsive spectrum disorders
|
DE60037818D1
(de)
|
1999-04-01 |
2008-03-06 |
Esperion Therapeutics Inc |
Ether-verbindungen, zusammensetzungen und ihre verwendung
|
CZ20013607A3
(cs)
|
1999-04-06 |
2002-06-12 |
Sepracor Inc. |
Farmaceutický prostředek
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
GB9908921D0
(en)
|
1999-04-19 |
1999-06-16 |
Britannia Pharmaceuticals Ltd |
Spray dispenser for opiod antagonists
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
PT1187603E
(pt)
|
1999-06-14 |
2007-11-16 |
Vivus Inc |
''terapia de associação para promover a perda de peso e o tratamento da obesidade''
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
DE19927688A1
(de)
|
1999-06-17 |
2000-12-21 |
Gruenenthal Gmbh |
Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
|
US20040115134A1
(en)
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
WO2001001973A2
(en)
|
1999-07-01 |
2001-01-11 |
Pharmacia & Upjohn Company |
Highly selective norepinephrine reuptake inhibitors and methods of using the same
|
US6500459B1
(en)
|
1999-07-21 |
2002-12-31 |
Harinderpal Chhabra |
Controlled onset and sustained release dosage forms and the preparation thereof
|
US6071918A
(en)
|
1999-07-21 |
2000-06-06 |
Dupont Pharmaceuticals Company |
Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
|
US6489350B1
(en)
|
1999-09-15 |
2002-12-03 |
Elan Pharmaceuticals, Inc. |
Methods for treating neuropathic pain using heteroarylmethanesulfonamides
|
US6387403B1
(en)
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
US6403657B1
(en)
|
1999-10-04 |
2002-06-11 |
Martin C. Hinz |
Comprehensive pharmacologic therapy for treatment of obesity
|
GB2355191A
(en)
|
1999-10-12 |
2001-04-18 |
Laxdale Ltd |
Combination formulations for fatigue, head injury and strokes
|
EP1220673A2
(en)
|
1999-10-13 |
2002-07-10 |
Glaxo Group Limited |
Morpholinol derivatives for the treatment of obesity
|
US6410736B1
(en)
|
1999-11-29 |
2002-06-25 |
Pfizer Inc. |
Biaryl ether derivatives useful as monoamine reuptake inhibitors
|
AR031682A1
(es)
|
1999-11-19 |
2003-10-01 |
Reckitt Benckiser Helthcare Uk |
Composiciones farmaceuticas
|
GB0001449D0
(en)
|
2000-01-21 |
2000-03-08 |
Cortendo Ab |
Compositions
|
US20020055512A1
(en)
|
2000-01-21 |
2002-05-09 |
Cortendo Ab. |
Compositions for delivery of a cortisol antagonist
|
WO2001052851A1
(en)
|
2000-01-22 |
2001-07-26 |
Albert Shulman |
Methods for the treatment of substance abuse
|
CA2397726A1
(en)
|
2000-01-22 |
2001-07-26 |
Albert Shulman |
Methods for the treatment of substance abuse
|
US20020090615A1
(en)
|
2000-01-31 |
2002-07-11 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
PT2277521E
(pt)
|
2000-02-08 |
2015-07-01 |
Euro Celtique Sa |
Formulações orais de agonistas de opióides resistentes a adulteração
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
CA2403252A1
(en)
|
2000-03-15 |
2001-09-20 |
Wolfgang Sadee |
Neutral antagonists and use thereof in treating drug abuse
|
WO2001068104A1
(en)
|
2000-03-16 |
2001-09-20 |
The Mclean Hospital Corporation |
Compounds for the treatment of psychiatric or substance abuse disorders
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
EP1272181A2
(en)
|
2000-04-13 |
2003-01-08 |
Synthon B.V. |
Modified release formulations containing a hypnotic agent
|
EP1275373A4
(en)
|
2000-04-17 |
2007-04-04 |
Astellas Pharma Inc |
DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
|
US6761895B2
(en)
|
2000-04-17 |
2004-07-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug delivery system for averting pharmacokinetic drug interaction and method thereof
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
JP2004515455A
(ja)
|
2000-05-05 |
2004-05-27 |
ペイン・セラピューティクス・インコーポレイテッド |
オピオイドアンタゴニスト組成物および投薬形態
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
AU2001280865A1
(en)
|
2000-08-02 |
2002-02-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
ES2310192T3
(es)
|
2000-09-18 |
2009-01-01 |
Sanos Bioscience A/S |
Uso de peptidos glp-2.
|
RU2197250C2
(ru)
|
2000-10-30 |
2003-01-27 |
Соколовский Сергей Ростиславович |
Способ лечения наркоманий
|
EP1333887B1
(en)
|
2000-10-30 |
2006-08-02 |
Ortho-McNeil Pharmaceutical, Inc. |
Combination therapy comprising anti-diabetic and anticonvulsant agents
|
US6569449B1
(en)
|
2000-11-13 |
2003-05-27 |
University Of Kentucky Research Foundation |
Transdermal delivery of opioid antagonist prodrugs
|
CA2445528A1
(en)
|
2001-04-26 |
2002-11-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
EP1262196A3
(en)
|
2001-05-23 |
2002-12-18 |
Pfizer Products Inc. |
Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
|
US6960357B2
(en)
|
2001-05-25 |
2005-11-01 |
Mistral Pharma Inc. |
Chemical delivery device
|
DK1411900T4
(da)
|
2001-06-01 |
2014-01-27 |
Pozen Inc |
Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
|
CN100356907C
(zh)
|
2001-06-08 |
2007-12-26 |
恩德制药公司 |
利用丙烯酸酯聚合物的控释剂型和其制备方法
|
US6462237B1
(en)
|
2001-06-14 |
2002-10-08 |
Usv Limited |
Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
|
KR20040060917A
(ko)
|
2001-08-06 |
2004-07-06 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 남용을 방지하기 위한 조성물 및 방법
|
SI1414451T1
(sl)
|
2001-08-06 |
2009-10-31 |
Euro Celtique Sa |
Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030087896A1
(en)
|
2001-08-09 |
2003-05-08 |
Hillel Glover |
Treatment of refractory depression with an opiate antagonist and an antidepressant
|
US20030044462A1
(en)
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
US6576256B2
(en)
|
2001-08-28 |
2003-06-10 |
The Brigham And Women's Hospital, Inc. |
Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
ITFI20010230A1
(it)
|
2001-11-29 |
2003-05-29 |
Menarini Int Operations Lu Sa |
Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
|
EP1455751A1
(en)
|
2001-12-20 |
2004-09-15 |
Pharmacia Corporation |
Zero-order sustained released dosage forms and method of making the same
|
US20040102440A1
(en)
|
2002-07-01 |
2004-05-27 |
Wong Erik Ho Fong |
Method of promoting smoking cessation
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US20040029941A1
(en)
|
2002-05-06 |
2004-02-12 |
Jennings Julianne E. |
Zonisamide use in obesity and eating disorders
|
US20050215552A1
(en)
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
CN1320886C
(zh)
|
2002-05-17 |
2007-06-13 |
杜克大学 |
安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
|
WO2003097051A2
(en)
|
2002-05-17 |
2003-11-27 |
Merck Patent Gmbh |
Use of compounds that are effective as selective opiate receptor modulators
|
US20040005368A1
(en)
|
2002-07-01 |
2004-01-08 |
Morris Mann |
Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
|
US6972291B2
(en)
|
2002-07-02 |
2005-12-06 |
Bernstein Richard K |
Method for reducing food intake
|
US20040258757A1
(en)
|
2002-07-16 |
2004-12-23 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
WO2004009015A2
(en)
|
2002-07-18 |
2004-01-29 |
Merck & Co., Inc. |
Combination therapy for the treatment of obesity
|
US7086532B2
(en)
|
2003-07-16 |
2006-08-08 |
Allergan, Inc. |
Titration/compliance pack with increasing doses
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
US7713551B2
(en)
|
2002-09-11 |
2010-05-11 |
Elan Pharma International Ltd. |
Gel stabilized nanoparticulate active agent compositions
|
EP1539145A2
(en)
|
2002-09-13 |
2005-06-15 |
Eisai Co., Ltd. |
Method of treating tremors
|
WO2004032980A1
(en)
|
2002-10-04 |
2004-04-22 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
US20040092504A1
(en)
|
2002-11-12 |
2004-05-13 |
Anuthep Benja-Athon |
Definitive medications for treating fibromyalgia
|
US6893660B2
(en)
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
US20040115265A1
(en)
|
2002-12-11 |
2004-06-17 |
Loutfy Benkerrour |
Multilayered tablet containing pravastatin and aspirin and method
|
JP2006514986A
(ja)
|
2002-12-13 |
2006-05-18 |
シラグ・アクチエンゲゼルシヤフト |
トラマドールおよびトピラメートを含んでなる制御放出調製物
|
CA2414500A1
(en)
|
2002-12-17 |
2004-06-17 |
Purepharm Inc. |
Agonist-aversive combination medicines
|
EP1575566B1
(en)
|
2002-12-26 |
2012-02-22 |
Pozen, Inc. |
Multilayer dosage forms containing naproxen and triptans
|
US20040185097A1
(en)
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
US20040192715A1
(en)
|
2003-02-05 |
2004-09-30 |
Mark Chasin |
Methods of administering opioid antagonists and compositions thereof
|
US20040158194A1
(en)
|
2003-02-06 |
2004-08-12 |
Wolff Andy And Beiski Ben Z. |
Oral devices and methods for controlled drug release
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
EP1772147A2
(en)
|
2003-03-17 |
2007-04-11 |
Japan Tobacco, Inc. |
Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
WO2004087175A1
(en)
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
WO2004091593A2
(en)
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
PL2316456T3
(pl)
|
2003-04-29 |
2017-12-29 |
Orexigen Therapeutics, Inc. |
Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion
|
RU2005135454A
(ru)
|
2003-05-16 |
2006-06-27 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
|
CA2525323A1
(en)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
EP1635813A4
(en)
|
2003-06-06 |
2009-07-01 |
Merck & Co Inc |
COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
|
US20060160834A1
(en)
|
2003-06-06 |
2006-07-20 |
Fong Tung M |
Combination therapy for the treatment of hypertension
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
WO2005009417A1
(en)
|
2003-07-21 |
2005-02-03 |
Noven Pharmaceuticals, Inc. |
Composition and method for controlling grug delivery from silicone adhesive blends
|
WO2005009377A2
(en)
|
2003-07-23 |
2005-02-03 |
University Of Kentucky Research Foundation |
Novel oral bioavailable prodrugs
|
JP2007501839A
(ja)
|
2003-08-08 |
2007-02-01 |
エラン ファーマ インターナショナル リミテッド |
新規メタキサロン組成物
|
MXPA05012637A
(es)
|
2003-08-08 |
2006-02-24 |
Biovail Lab Int Srl |
Tableta de liberacion modificada del clorhidrato de bupropion.
|
US20050043773A1
(en)
|
2003-08-21 |
2005-02-24 |
Ivan Lieberburg |
Methods of improving the safety of zonisamide therapy
|
WO2005018652A1
(en)
|
2003-08-21 |
2005-03-03 |
Duchesnay Inc. |
Micronutrient supplement
|
US20050043705A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd. |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
US20050043704A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
JP4758897B2
(ja)
|
2003-09-25 |
2011-08-31 |
ユーロ−セルティーク エス.エイ. |
ヒドロコドンとナルトレキソンとの併用医薬
|
US20050112198A1
(en)
|
2003-10-27 |
2005-05-26 |
Challapalli Prasad V. |
Bupropion formulation for sustained delivery
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
US20050147664A1
(en)
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
US20070149451A1
(en)
|
2003-11-17 |
2007-06-28 |
Holmes David G |
Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
|
WO2005049043A1
(en)
|
2003-11-18 |
2005-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Combination therapy comprising metformin and anticonvulsant agents
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
CA2552221A1
(en)
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Donepezil formulations
|
US20060160750A1
(en)
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
AU2005206139B2
(en)
|
2004-01-13 |
2009-02-26 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
EP1727538A2
(en)
|
2004-02-13 |
2006-12-06 |
Neuromolecular Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
SE0400378D0
(sv)
|
2004-02-17 |
2004-02-17 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
WO2005092297A2
(en)
|
2004-03-03 |
2005-10-06 |
Teva Pharmaceutical Industries Ltd. |
A stable pharmaceutical composition comprising an acid labile drug
|
US20050245541A1
(en)
|
2004-03-19 |
2005-11-03 |
Elliot Ehrich |
Methods for treating alcoholism
|
US20060100205A1
(en)
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
EP1748776A1
(en)
|
2004-05-03 |
2007-02-07 |
Duke University |
Compositions for affecting weight loss
|
US20050250838A1
(en)
|
2004-05-04 |
2005-11-10 |
Challapalli Prasad V |
Formulation for sustained delivery
|
JP2008509142A
(ja)
|
2004-08-03 |
2008-03-27 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
体重減少に影響を及ぼすためのブプロピオンと第2の化合物との組合せ
|
DK1781265T3
(da)
|
2004-08-25 |
2010-08-02 |
Essentialis Inc |
Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
|
EP1809104A4
(en)
|
2004-09-23 |
2009-04-29 |
Alexander Michalow |
METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
|
EP1804785A2
(en)
|
2004-10-27 |
2007-07-11 |
Neurogen Corporation |
Diaryl ureas as cb1 antagonists
|
WO2006052542A2
(en)
|
2004-11-04 |
2006-05-18 |
Neurogen Corporation |
Arylalkyl ureas as cb1 antagonists
|
US20060122127A1
(en)
|
2004-11-17 |
2006-06-08 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtzapine treatment
|
JP2006232675A
(ja)
|
2005-02-22 |
2006-09-07 |
Kowa Co |
複合型口腔内溶解用固形製剤
|
JP2008536950A
(ja)
|
2005-04-18 |
2008-09-11 |
ニューロジェン・コーポレーション |
置換ヘテロアリールのcb1拮抗薬
|
US20060246131A1
(en)
|
2005-04-28 |
2006-11-02 |
Cottlingham Elizabeth M |
Use of metformin to counteract weight gain associated with psychotropic medications
|
CA2609193A1
(en)
|
2005-05-31 |
2006-12-07 |
Orexigen Therapeutics, Inc. |
Methods and compositions for managing psychotic disorders
|
US20070021352A1
(en)
|
2005-07-20 |
2007-01-25 |
Cypress Bioscience, Inc. |
Prevention and treatment of hearing disorders
|
MX2008001136A
(es)
|
2005-07-27 |
2008-03-13 |
Orexigen Therapeutics Inc |
Composiciones para afectar la perdida de peso.
|
PL2347762T3
(pl)
|
2005-08-19 |
2019-09-30 |
Amylin Pharmaceuticals, Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
WO2007047351A2
(en)
|
2005-10-13 |
2007-04-26 |
Orexigen Therapeutics, Inc. |
Methods for treating hypertension in overweight and obese individuals
|
US20070099947A1
(en)
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
DK2135603T3
(da)
|
2005-11-22 |
2013-03-25 |
Orexigen Therapeutics Inc |
Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
|
WO2007089318A2
(en)
|
2005-11-23 |
2007-08-09 |
Orexigen Therapeutics, Inc. |
Compositions and methods for reducing food cravings
|
ES2383330T3
(es)
|
2005-11-28 |
2012-06-20 |
Orexigen Therapeutics, Inc. |
Formulación de liberación sostenida de zonisamida
|
JP2009517393A
(ja)
|
2005-11-28 |
2009-04-30 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
不安症の治療方法
|
WO2007084290A2
(en)
|
2006-01-12 |
2007-07-26 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
|
EP1813276A1
(en)
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
ES2749800T3
(es)
*
|
2006-06-05 |
2020-03-23 |
Nalpropion Pharmaceuticals Llc |
Formulación de liberación sostenida de naltrexona
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
KR101486228B1
(ko)
|
2006-06-19 |
2015-01-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
CA2693992C
(en)
|
2006-07-20 |
2017-01-31 |
Somaxon Pharmaceuticals, Inc. |
Methods of improving the pharmacokinetics of doxepin
|
US8682445B2
(en)
|
2006-07-28 |
2014-03-25 |
Cyberonics, Inc. |
Patient management system for treating depression using an implantable medical device
|
WO2008060964A2
(en)
|
2006-11-09 |
2008-05-22 |
Orexigen Therapeutics, Inc. |
Unit dosage package and methods for administering weight loss medications
|
US8088786B2
(en)
|
2006-11-09 |
2012-01-03 |
Orexigen Therapeutics, Inc. |
Layered pharmaceutical formulations
|
GB2447949B
(en)
|
2007-03-29 |
2010-03-31 |
Renasci Consultancy Ltd |
A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
|
RU2342195C1
(ru)
|
2007-04-18 |
2008-12-27 |
Институт проблем комплексного освоения недр РАН |
Устройство для механоактивации сульфидсодержащих минеральных продуктов
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US20110144145A1
(en)
|
2008-05-30 |
2011-06-16 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
US9248123B2
(en)
|
2010-01-11 |
2016-02-02 |
Orexigen Therapeutics, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
EP2642988A1
(en)
|
2010-11-26 |
2013-10-02 |
Ramot at Tel-Aviv University Ltd |
Method and composition for weight-gain management
|
US20130245056A1
(en)
|
2010-12-03 |
2013-09-19 |
Orexigen Therapeutics, Inc. |
Increasing drug bioavailability in naltrexone therapy
|
HUE034641T2
(en)
|
2010-12-03 |
2018-02-28 |
Orexigen Therapeutics Inc |
Procedure for reducing overeating or forced eating
|
ES2802048T3
(es)
*
|
2012-06-06 |
2021-01-15 |
Nalpropion Pharmaceuticals Llc |
Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
|
US8969371B1
(en)
*
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|